RxDoctor Payments Data

Jamie Doughty, NP

Nurse Practitioner · Columbus, INNPI 1144952342

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 58 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$210
  • Lilly USA, LLC$189
  • GSK$121
  • Endologix LLC$94
  • AbbVie$71
  • Stryker$67
  • plus $499 from 17 others

What the payments were for

  • Food & beverage$1,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$61,188
Medicare patients
355
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$13,209
EliquisApixaban13$8,601
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,710
ClopidogrelClopidogrel Bisulfate54$444
Levothyroxine Sodium35$432
Atorvastatin Calcium66$380
Pravastatin Sodium21$377
Albuterol Sulfate HfaAlbuterol Sulfate18$360
Fluticasone Propionate19$333
Potassium Chloride17$317
Tamsulosin Hcl15$307
Omeprazole26$285
Escitalopram Oxalate12$283
Losartan Potassium14$230
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$189$13,20912 claims
PfizerEliquis$29$8,60113 claims
Boehringer IngelheimStiolto Respimat$24$5,71012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$43235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →